Arvinas shows strong ESR1-mutant data with limited scope, niche SERD competition, Pfizer uncertainty, and a high-risk pipeline. See why ARVN stock is a hold.
Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Invivyd intends to grant the underwriters an ...
Additional analysis of data from a Phase 1b clinical trial that included all patients treated with gedatolisib combined with fulvestrant and palbociclib showed median progression-free survival (“PFS”) ...
They are simple and sweet. Sometimes a little treat can make the day brighter. While that sweet indulgence satisfies, no one wants a small bite to derail other healthy food choices. These simple, easy ...
Europe’s dairy and poultry producers are having a moment as the global trend toward high-protein diets intensifies, in a stark contrast with Big Food’s struggle to revive volumes. British meat ...
NEW YORK – Roche on Wednesday said the European Commission approved Itovebi (inavolisib) with Pfizer's CDK4/6 inhibitor Ibrance (palbociclib) and fulvestrant as a treatment for patients with ...
WASHINGTON, 2nd June, 2025 (WAM) -- A new triple therapy for aggressive, advanced breast cancer slows the progression of the disease, delays the need for further chemotherapy and helps patients live ...
1 Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, China 2 School of Pharmacy, Changchun University of Chinese Medicine, Changchun, China Depression is a psychological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback